Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy

被引:6
作者
Zhong, Zichen [1 ]
Deng, Wen [1 ]
Wu, Jian [1 ]
Shang, Haojie [1 ]
Tong, Yonghua [1 ]
He, Yu [1 ]
Huang, Qiu [1 ]
Ba, Xiaozhuo [1 ]
Chen, Zhiqiang [1 ]
Tang, Kun [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan 430030, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
POLYMERIC NANOPARTICLES; EXTRACELLULAR VESICLES; ANTICANCER VACCINATION; MAGNETIC NANOPARTICLES; TUMOR; THERAPY; NANOVACCINE; RESISTANCE; MICROENVIRONMENT; NANOSYSTEM;
D O I
10.1039/d4nr00284a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cancer immunotherapy, a burgeoning modality for cancer treatment, operates by activating the autoimmune system to impede the growth of malignant cells. Although numerous immunotherapy strategies have been employed in clinical cancer therapy, the resistance of cancer cells to immunotherapeutic medications and other apprehensions impede the attainment of sustained advantages for most patients. Recent advancements in nanotechnology for drug delivery hold promise in augmenting the efficacy of immunotherapy. However, the efficacy is currently constrained by the inadequate specificity of delivery, low rate of response, and the intricate immunosuppressive tumor microenvironment. In this context, the investigation of cell membrane coated nanoparticles (CMNPs) has revealed their ability to perform targeted delivery, immune evasion, controlled release, and immunomodulation. By combining the advantageous features of natural cell membranes and nanoparticles, CMNPs have demonstrated their unique potential in the realm of cancer immunotherapy. This review aims to emphasize recent research progress and elucidate the underlying mechanisms of CMNPs as an innovative drug delivery platform for enhancing cancer immunotherapy. Additionally, it provides a comprehensive overview of the current immunotherapeutic strategies involving different cell membrane types of CMNPs, with the intention of further exploration and optimization. Graphical abstract of CMNPs delivering different therapeutic agents for enhancing cancer immunotherapy.
引用
收藏
页码:8708 / 8738
页数:31
相关论文
共 217 条
  • [41] Cancer immunotherapy comes of age and looks for maturity
    Finck, Amanda
    Gill, Saar I.
    June, Carl H.
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [42] Tumor cell membrane-camouflaged responsive nanoparticles enable MRI-guided immuno-chemodynamic therapy of orthotopic osteosarcoma
    Fu, Liwen
    Zhang, Weiying
    Zhou, Xiaojun
    Fu, Jingzhong
    He, Chuanglong
    [J]. BIOACTIVE MATERIALS, 2022, 17 : 221 - 233
  • [43] Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines
    Gao, Cheng
    Huang, Qiaoxian
    Liu, Conghui
    Kwong, Cheryl H. T.
    Yue, Ludan
    Wan, Jian-Bo
    Lee, Simon M. Y.
    Wang, Ruibing
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [44] Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy
    Gao, Jing
    Liang, Yuanzheng
    Wang, Liang
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
    Garris, Christopher S.
    Arlauckas, Sean P.
    Kohler, Rainer H.
    Trefny, Marcel P.
    Garren, Seth
    Piot, Cecile
    Engblom, Camilla
    Pfirschke, Christina
    Siwicki, Marie
    Gungabeesoon, Jeremy
    Freeman, Gordon J.
    Warren, Sarah E.
    Ong, Sufey
    Browning, Erica
    Twitty, Christopher G.
    Pierce, Robert H.
    Le, Mai H.
    Algazi, Alain P.
    Daud, Adil I.
    Pai, Sara I.
    Zippelius, Alfred
    Weissleder, Ralph
    Pittet, Mikael J.
    [J]. IMMUNITY, 2018, 49 (06) : 1148 - +
  • [46] Tumor microenvironment signaling and therapeutics in cancer progression
    Goenka, Anshika
    Khan, Fatima
    Verma, Bhupender
    Sinha, Priyanka
    Dmello, Crismita C.
    Jogalekar, Manasi P.
    Gangadaran, Prakash
    Ahn, Byeong-Cheol
    [J]. CANCER COMMUNICATIONS, 2023, 43 (05) : 525 - 561
  • [47] Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles
    Gong, Chunai
    Yu, Xiaoyan
    Zhang, Wei
    Han, Lu
    Wang, Rong
    Wang, Yujie
    Gao, Shen
    Yuan, Yongfang
    [J]. JOURNAL OF NANOBIOTECHNOLOGY, 2021, 19 (01)
  • [48] Nanomaterials for T-cell cancer immunotherapy
    Gong, Ningqiang
    Sheppard, Neil C.
    Billingsley, Margaret M.
    June, Carl H.
    Mitchell, Michael J.
    [J]. NATURE NANOTECHNOLOGY, 2021, 16 (01) : 25 - 36
  • [49] Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist
    Gou, Shanshan
    Liu, Wenwen
    Wang, Shuai
    Chen, Guanyu
    Chen, Zhenzhen
    Qiu, Lu
    Zhou, Xiuman
    Wu, Yahong
    Qi, Yuanming
    Gao, Yanfeng
    [J]. NANO LETTERS, 2021, 21 (23) : 9939 - 9950
  • [50] Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
    Gowd, Vemana
    Ahmad, Anas
    Tarique, Mohammad
    Suhail, Mohd
    Zughaibi, Torki A.
    Tabrez, Shams
    Khan, Rehan
    [J]. SEMINARS IN CANCER BIOLOGY, 2022, 86 : 624 - 644